![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1722859
¼¼°èÀÇ ¼Ò¾Æ ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, ¿¹Ãø : µð¹ÙÀ̽º À¯Çü, ½Ã¼ú, ÃÖÁ¾ ¿ëµµ, Áö¿ªº°(2025-2033³â)Pediatric Interventional Cardiology Market Size, Share, Trends and Forecast by Device Type, Procedure, End Use, and Region 2025-2033 |
¼Ò¾Æ ½ÉÇ÷°ü ÁßÀç½Ã¼ú ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 27¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ÀÌ ½ÃÀåÀÌ 2033³â±îÁö 45¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â 5.45%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ÇöÀç ºÏ¹Ì°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, 2024³â ½ÃÀå Á¡À¯À²Àº 35.8%¸¦ ÃʰúÇß½À´Ï´Ù. ¼±Ãµ¼º ½ÉÀ庴 À¯º´·ü Áõ°¡, ±Þ¼ÓÇÑ ±â¼ú ¹ßÀü, ÃÖ¼Òħ½À(MI) ½Ã¼ú¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, ÀÎ½Ä °³¼± ¹× Á¶±â Áø´Ü ³ë·Â, Á¤ºÎ Áö¿ø Á¤Ã¥ ½ÃÇà, ¼Ò¾Æ Àα¸ Áõ°¡, ÀÇ·á ÀÎÇÁ¶ó °³¼± µîÀÌ ¼Ò¾Æ ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå Á¡À¯À²À» ³ôÀÌ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½ÃÀå Á¡À¯À²À» ³ôÀÌ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
¼Ò¾ÆÁßÀç½ÉÀåÇÐÀº ½ÉÀ庴ÇÐÀÇ ÇÏÀ§ ºÐ¾ß·Î, ¿µ¾Æ, ¼Ò¾Æ, 18¼¼ ÀÌÇÏÀÇ Ã»¼Ò³âÀÇ ½ÉÀåÁúȯÀ» Ä¡·áÇϱâ À§ÇØ Æ¯Á¤ Ä«Å×ÅÍ ±â¹Ý ±â¼úÀ» »ç¿ëÇÏ´Â ºÐ¾ßÀÔ´Ï´Ù. dz¼± Ç÷°ü ¼ºÇü¼ú, ÄÚÀÏ Æó»ö¼ú, ½ºÅÙÆ® »ðÀÔ¼ú, ´ëµ¿¸ÆÆÇ¸· ÇùÂøÁõ µîÀÌ Æ÷ÇԵ˴ϴÙ. ±âÁ¸ÀÇ ½ÉÀ庴 Ä¡·á¿¡ ºñÇØ ¼Ò¾Æ ½ÉÇ÷°ü ÁßÀç½Ã¼úÀº ÃÖ¼Ò Ä§½ÀÀûÀ̱⠶§¹®¿¡ ¼ö¼ú ÈÄ ÇÕº´ÁõÀÌ Àû½À´Ï´Ù. µû¶ó¼ Ç÷°ü¼ºÇü¼ú, ÆÇ¸·¼ºÇü¼ú, °ü»óµ¿¸Æ Ç÷ÀüÁ¦°Å¼ú, ¼±Ãµ¼º ½ÉÀåÁúȯ ±³Á¤¼ú µî ÀÓ»ó°Ë»ç±â°ü, º´¿ø, ½ÉÀå¼¾ÅÍ, ¿¬±¸±â°ü µî¿¡¼ Æø³Ð°Ô äÅõǰí ÀÖ½À´Ï´Ù.
½É¹æÁ߰ݰá¼ÕÁõ(ASD), ½É¹æ¼¼µ¿, µ¿¸Æ°ü°³Á¸Áõ(PDA), ½É½ÇÁ߰ݰá¼ÕÁõ(VSD) µî ¼Ò¾Æ¿¡¼ ´Ù¾çÇÑ ¼±Ãµ¼º ½ÉÀåÁúȯ Áõ°¡´Â ¼Ò¾Æ ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. Ä«Å×ÅÍ, »ýü Èí¼ö¼º ½ºÅÙÆ®, °¡À̵å¿ÍÀ̾î, dz¼±, ½ºÅÙÆ®, Ç÷°ü Æó¼â ÀåÄ¡, µ¿¸Æ ÀýÁ¦¼ú ÀåÄ¡ µî »õ·Ó°í È¿À²ÀûÀÎ ¼Ò¾Æ ½ÉÇ÷°ü ÁßÀç½Ã¼ú ÀåÄ¡ÀÇ µµÀÔµµ ¶Ç ´Ù¸¥ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ºñħ½ÀÀû ÀÇ·á ½Ã¼ú¿¡ ´ëÇÑ È¯ÀÚµéÀÇ ¼±È£µµ º¯È¿Í °¨¿° À§Çè °¨¼Ò, ¼ö¼ú ÈÄ È¸º¹ ½Ã°£ ´ÜÃà, Å« ÈäÅÍ ¹æÁö µî °ü·Ã ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ ½ÃÀå ¼ºÀå¿¡ ÈûÀ» º¸Å°í ÀÖ½À´Ï´Ù. ´Ù¸¥ ¿äÀÎÀ¸·Î´Â ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í ±ÔÁ¦ ÀýÂ÷¸¦ °¡¼ÓÈÇϱâ À§ÇØ °¢±¹ Á¤ºÎ°¡ ÃëÇÑ ¿©·¯ °¡Áö ³ë·ÂÀ¸·Î ÀÎÇØ ½ÃÀå Àü¸ÁÀÌ ¹à¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿, ¼ÒºñÀÚ ÀÇ·áºñ Áõ°¡, ±âÁ¸ ÀÇ·á ÀÎÇÁ¶ó¸¦ °ÈÇϱâ À§ÇÑ Á¤ºÎ ¹× ºñÁ¤ºÎ±â±¸(NGO)ÀÇ ÅõÀÚ, ½ÉÀ庴ÇÐ ºÐ¾ßÀÇ »ó´çÇÑ ±â¼ú ¹ßÀüµµ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
The global pediatric interventional cardiology market size was valued at USD 2.78 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 4.58 Billion by 2033, exhibiting a CAGR of 5.45% during 2025-2033. North America currently dominates the market, holding a market share of over 35.8% in 2024. The rising congenital heart disease prevalence, rapid technological advancements, increasing preference for minimally invasive (MI) procedures, expanded awareness and early diagnosis initiatives, imposition of supportive government policies, a growing pediatric population, and enhanced healthcare infrastructure, are major factors bolstering the pediatric interventional cardiology market share.
Pediatric interventional cardiology is a subset of cardiology that involves the use of specific catheter-based techniques to treat heart disorders in infants, children, and adolescents upto 18 years of age. They include balloon angioplasty, coil occlusion, stent implantation, and aortic valve stenosis. As compared to conventional cardiological treatments, pediatric interventional cardiology is more minimally invasive, thus reducing post-surgerycomplications. Consequently, they are extensively employed for performing angioplasty, valvuloplasty, coronary thrombectomy, and congenital heart defect correction procedures across clinical testing laboratories, hospitals, cardiac centers, and research institutes.
Theincreasing instances of various congenital cardiac diseases in children, such as atrial septal defect (ASD), atrioventricular canal defect, patent ductus arteriosus (PDA), and ventricular septal defect (VSD) represent one of the key factors driving the pediatric interventional cardiology market growth. The introduction of novel and more efficient pediatric interventional cardiology devices, including catheters, bio-absorbable stents, guidewires, balloons, stents, vascular closure devices, atherectomy devices is acting as another major growth-inducing factor.In line with this, the shifting inclination of patients toward non-invasive medical treatment procedures, along with the rising awareness regarding the associated benefits, such as lower risk of infection, shorter postoperative recovery times, and avoidance of large scars is also driving the market growth. Other factors, including rising healthcare expenditure and the numerous initiatives being undertaken by governments of various nations to speed-up regulatory procedures, are creating a positive outlook for the market. The market is also driven by extensive research and development (R&D) activities, increasing consumer healthcare expenditure and investments by governments and non-government organizations (NGOs) for strengthening the existing healthcare infrastructure, and significant technological advancements in the field of cardiology.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Biotronik SE & Co. KG, Boston Scientific Corporation, Cardinal Health Inc., Edwards Lifesciences Corporation, General Electric Company, Koninklijke Philips N.V., Lepu Medical Technology (Beijing) Co. Ltd., Medtronic plc, NuMED Inc., Siemens Healthineers AG, Terumo Corporation and W. L. Gore & Associates Inc.